huC242-DM4

DRUG2 trials

Sponsors

ImmunoGen, Inc.

Conditions

Metastatic or Local Advanced GE Junction CancerMetastatic or Locally Advanced Gastric CancerNon-colorectal CancerPancreatic CancerStomach Neoplasms

Phase 1

Maytansinoid DM4-Conjugated Humanized Monoclonal Antibody huC242 in Treating Patients With Solid Tumors

CompletedNCT00352131

ImmunoGen, Inc.Non-colorectal Cancer, Pancreatic Cancer

Start: 2005-02-28End: 2009-12-31Target: 50Updated: 2010-03-17

Phase 2

huC242-DM4 Treating Patients With Metastatic Gastric or Gastroesophageal Junction Carcinomas

WithdrawnNCT00620607

ImmunoGen, Inc.Metastatic or Local Advanced GE Junction Cancer, Metastatic or Locally Advanced Gastric Cancer, Stomach Neoplasms

Start: 2007-05-31End: 2010-09-30Updated: 2015-08-26